Erratum: Dual HER2 blockade: Preclinical and clinical data [Breast Cancer Research, (2014)]. DOI: 10.1186/s13058-014-0419-5

Tejal A. Patel, Bhuvanesh Dave, Angel A. Rodriguez, Jenny C. Chang, Edith A. Perez, Gerardo Colon-Otero

Research output: Contribution to journalComment/debate

Abstract

After publication of our review [1], we noted errors to the legend of Figure 1B, C. The ado-trastuzumab-emtansine concentration should be 1 μg/ml instead of 1 mg/ml. The trastuzumab concentration should be 10 μg/ml instead of 10 mg/ml. The lapatinib concentration should be 10 μM instead of 10 mM (Please see Figure 1, a corrected version of the original Figure 1).

Original languageEnglish (US)
Article number468
JournalBreast Cancer Research
Volume16
Issue number1
DOIs
StatePublished - Nov 6 2014

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Erratum: Dual HER2 blockade: Preclinical and clinical data [Breast Cancer Research, (2014)]. DOI: 10.1186/s13058-014-0419-5'. Together they form a unique fingerprint.

  • Cite this